respiratori
mucosa
primari
portal
entri
numer
virus
respiratori
syncyti
viru
influenza
viru
parainfluenza
viru
pathogen
initi
infect
upper
respiratori
tract
reach
lower
respiratori
tract
lead
diseas
vaccin
afford
way
control
pathogen
virus
constitut
strategi
choic
fight
infect
includ
lead
pulmonari
diseas
convent
vaccin
base
liveattenu
pathogen
present
risk
revers
pathogen
virul
inactiv
pathogen
vaccin
often
lead
weak
immun
respons
subunit
vaccin
develop
overcom
issu
howev
vaccin
may
suffer
limit
immunogen
case
protect
induc
partial
new
gener
vaccin
base
nanoparticl
shown
great
potenti
address
limit
convent
subunit
vaccin
due
recent
advanc
chemic
biolog
engin
allow
design
nanoparticl
precis
control
size
shape
function
surfac
properti
lead
enhanc
antigen
present
strong
immunogen
short
review
provid
overview
advantag
associ
use
nanoparticl
vaccin
deliveri
platform
immun
respiratori
virus
highlight
relev
exampl
demonstr
potenti
safe
effect
afford
vaccin
lower
respiratori
tract
infect
lrti
constitut
major
public
health
burden
worldwid
lrti
repres
lead
caus
human
mortal
morbid
caus
annual
million
death
worldwid
among
infect
lrti
case
caus
virus
case
pathogen
enter
host
via
airborn
transmiss
eg
droplet
aerosol
replic
effici
respiratori
tract
caus
clinic
manifest
rang
fever
bronchiol
pneumonia
addit
lrti
associ
virus
repres
import
sourc
econom
loss
livestock
poultri
industri
infect
predispos
anim
secondari
bacteri
infect
virus
infect
human
lower
respiratori
tract
includ
influenza
viru
respiratori
syncyti
viru
rsv
parainfluenza
viru
adenoviru
season
influenza
viru
epidem
result
signific
burden
diseas
children
elderli
account
million
case
sever
ill
nearli
death
worldwid
year
rsv
parainfluenza
viru
infect
lead
caus
hospit
acut
respiratori
infect
young
children
caus
pediatr
hospit
respect
adenoviru
infect
account
lrti
case
children
fatal
immunocompromis
patient
gener
respiratori
virus
repres
major
health
problem
infant
young
children
immunocompromis
patient
elderli
popul
accord
global
burden
diseas
gbd
death
associ
lrti
repres
vulner
patient
group
vaccin
remain
costeffect
strategi
fight
infecti
diseas
convent
vaccin
formul
consist
attenu
virus
kill
pathogen
inactiv
subunit
protein
antigen
elicit
specif
immun
respons
vaccin
formul
allow
prevent
control
sever
import
diseas
includ
rubella
yellow
fever
polio
measl
case
smallpox
even
erad
consider
effort
devot
develop
effici
vaccin
lrti
includ
inactivatedfrag
trival
quadrival
season
vaccin
influenza
type
type
b
virus
influvac
r
vaxigrip
r
fluzon
r
well
live
attenu
vaccin
nasovac
r
flumist
r
nasal
administr
young
children
nevertheless
liveattenu
vaccin
influenza
viru
suffer
safeti
concern
due
natur
repres
risk
elderli
immunosuppress
human
besid
kill
pathogen
vaccin
virusderiv
subunit
vaccin
induc
weaker
immun
respons
often
requir
use
adjuv
boost
effici
sever
promis
vaccin
current
evalu
clinic
differ
respiratori
virus
new
vaccin
formul
aim
safer
effici
compar
tradit
vaccin
base
attenu
virus
kill
pathogen
subunit
nevertheless
high
level
antigen
drift
genet
mutat
virus
influenza
viru
reduc
efficaci
vaccin
need
address
therefor
improv
safeti
effici
vaccin
also
less
sensit
antigen
drift
concept
univers
vaccin
critic
virus
like
influenza
viru
new
formul
induc
broadspectrum
immun
investig
next
section
discuss
advantag
use
nanoparticl
formul
respiratori
virus
highlight
relev
exampl
use
nanoparticl
safe
effect
afford
vaccin
use
particl
nanoplatform
display
relev
antigen
moieti
appeal
altern
approach
convent
vaccin
nanos
materi
obtain
biolog
sourc
andor
synthet
current
larg
varieti
particl
evalu
antigen
carrier
includ
inorgan
polymer
nanoparticl
viruslik
particl
vlp
liposom
selfassembl
protein
nanoparticl
figur
advantag
materi
resid
primarili
size
least
one
dimens
nanomet
level
sinc
mani
biolog
system
virus
protein
nanos
nanoparticl
administ
via
subcutan
intramuscular
inject
deliv
mucos
site
oral
intranas
penetr
capillari
well
mucos
surfac
recent
progress
allow
prepar
nanoparticl
uniqu
physicochem
properti
instanc
size
shape
solubl
surfac
chemistri
hydrophil
tune
control
allow
prepar
nanoparticl
tailor
biolog
properti
moreov
nanoparticl
design
allow
incorpor
wide
rang
molecul
includ
antigen
make
highli
interest
vaccinolog
incorpor
antigen
nanoparticl
achiev
encapsul
physic
entrap
conjug
coval
function
studi
demonstr
nanoparticl
could
protect
nativ
structur
antigen
proteolyt
degrad
andor
improv
antigen
deliveri
antigenpres
cell
apc
addit
nanoparticl
incorpor
antigen
exert
local
depot
effect
ensur
prolong
antigen
present
immun
cell
interestingli
nanoparticl
also
shown
intrins
immunomodulatori
activ
instanc
nanoparticl
carbon
nanotub
cnt
carbon
black
nanoparticl
poli
lacticcoglycol
acid
plga
polystyren
nanoparticl
titanium
dioxid
tio
nanoparticl
silicon
dioxid
sio
nanoparticl
aluminum
oxyhydroxid
nanoparticl
report
induc
inflammasom
activ
fact
intern
apc
nanoparticl
provid
signal
trigger
lysosom
destabil
product
reactiv
oxygen
speci
ro
lead
releas
lysosom
content
includ
cystein
proteas
cathepsin
b
proteas
sens
subsequ
activ
format
inflammasom
complex
subsequ
interleukin
produc
downstream
signal
event
lead
recruit
andor
activ
immun
cell
taken
togeth
properti
advoc
nanoparticl
promis
antigen
carrier
immun
cell
activ
vaccin
respiratori
mucosa
repres
primari
site
invas
infect
viru
whose
replic
occur
ciliat
cell
upper
respiratori
tract
urt
subsequ
infect
spread
low
respiratori
tract
lrt
virusrich
secret
infect
cell
debri
urt
nasalassoci
lymphoid
tissu
nalt
first
site
inhal
antigen
recognit
locat
urt
import
line
defens
respiratori
virus
nalt
present
rodent
bird
primat
structur
character
aggreg
lymphoid
cell
locat
nasopharyng
caviti
human
waldev
ring
made
adenoid
tonsil
consid
equival
nalt
structur
contain
variou
narrow
epitheli
channel
nalt
compris
aggreg
lymphoid
follicl
bcell
area
interfollicular
area
tcell
area
macrophag
dendrit
cell
dc
figur
activ
support
clearanc
infecti
agent
accordingli
nalt
consid
induct
site
humor
cellular
immun
respons
repres
promis
target
vaccin
respiratori
virus
ideal
nanovaccin
would
follow
path
similar
respiratori
virus
order
effici
deliv
antigen
nalt
trigger
specif
mucos
immun
respons
therefor
formul
size
antigen
exposit
critic
aspect
design
nanovaccin
target
nalt
respiratori
virus
averag
diamet
size
rang
nm
thu
addit
safe
immunogen
nanovaccin
size
similar
virus
incorpor
relev
antigen
last
decad
number
nanoparticl
design
mimic
respiratori
virus
term
size
shape
surfac
properti
order
target
nalt
well
rais
humor
cellular
immun
respons
first
besid
nanoparticl
size
nm
diamet
match
size
respiratori
virus
nanoparticl
prefer
posit
charg
fact
posit
charg
polymer
phospholipid
metal
inorgan
proteinbas
nanoparticl
shown
stronger
immun
respons
compar
neg
charg
counterpart
second
incorpor
antigensepitop
within
surfac
nanoparticl
challeng
requir
advanc
approach
chemic
andor
biolog
engin
common
strategi
encapsul
entrap
antigensepitop
within
nanoparticl
case
nanoparticl
use
protect
antigenepitop
deliv
nalt
nanoencapsul
achiev
use
differ
procedur
includ
nanoprecipit
oil
water
ow
emuls
altern
antigen
attach
expos
nanoparticl
surfac
strategi
aim
mimick
virus
conjug
antigen
epitop
perform
directli
nanoparticl
use
differ
chemic
reaction
like
disulfid
bond
thiolategold
bond
format
otherwis
achiev
first
prepar
epitopefunction
selfassembl
unit
upon
selfassembl
form
nanoparticl
decor
antigen
third
formul
administr
strategi
also
critic
aspect
consid
vaccin
administ
via
subcutan
intramuscular
inject
induc
system
immun
usual
weak
mucos
respons
observ
hand
mucos
vaccin
either
oral
intranas
deliveri
induc
humor
cellular
immun
respons
system
level
mucos
surfac
effect
protect
respiratori
virus
studi
demonstr
vaccin
via
intranas
rout
provid
better
protect
compar
subcutan
immun
context
respiratori
pathogen
mucos
immun
intranas
vaccin
led
higher
antigenspecif
lymphocyt
prolifer
cytokin
product
interleukin
induct
antigenspecif
iga
antibodi
promis
formul
strategi
intranas
spray
deliv
conveni
safe
nanovaccin
directli
respiratori
mucosa
howev
number
clinic
trial
use
nanovaccin
formul
intranas
deliveri
includ
spray
dri
nanovaccin
limit
mostli
associ
difficulti
keep
nanovaccin
integr
entir
formul
process
moreov
immun
respons
particularli
sensit
natur
size
shape
surfac
properti
nanoparticl
well
densiti
potenc
antigen
thu
challeng
predict
effect
given
nanovaccin
immun
system
addit
nanoparticl
limit
associ
synthesi
prepar
properti
includ
limit
antigen
load
low
synthesi
yield
poor
target
capabl
immun
cell
limit
manufactur
case
toxic
drawback
lead
side
effect
andor
poor
immunogen
preclud
clinic
usag
besid
littl
known
interact
nanoparticl
immun
cell
fact
adjuv
effect
abil
activ
immun
system
still
remain
unclear
need
better
understood
molecular
level
nonetheless
nanoparticl
formul
recent
reveal
promis
result
respiratori
viru
infect
tabl
relev
exampl
discuss
polym
consist
larg
molecul
construct
monomer
unit
depend
construct
polym
linear
slightli
branch
hyperbranch
network
polymer
nanoparticl
either
obtain
polymer
monomer
unit
preform
polym
nanoparticl
attract
medic
field
due
adjust
properti
size
composit
surfac
properti
allow
control
releas
abil
combin
therapi
imag
theranost
protect
drug
molecul
exampl
poli
lacticcoglycol
acid
plga
biodegrad
biocompat
polym
approv
food
drug
administr
fda
european
medicin
agenc
ema
use
human
due
abil
undergo
hydrolysi
vivo
result
lactic
acid
glycol
acid
metabolit
effici
process
bodi
plga
engin
form
nanoparticl
capabl
encapsul
differ
type
biomolecul
releas
sustain
time
nanoparticl
encapsul
antigen
prevent
degrad
week
physiolog
condit
critic
mucos
vaccin
moreov
plganp
promot
antigen
intern
apc
facilit
antigen
process
present
lymphocyt
instanc
spheric
plganp
nm
diamet
use
encapsul
inactiv
swine
influenza
viru
swiv
antigen
kag
via
wateroilwat
doubl
emuls
solvent
evapor
observ
pig
vaccin
twice
prepar
challeng
virul
heterolog
influenza
viru
strain
significantli
milder
diseas
comparison
nonvaccin
anim
observ
correl
close
reduc
lung
patholog
substanti
clearanc
viru
anim
lung
polymer
nanoparticl
chitosan
natur
polym
compos
randomli
distribut
link
dglucosamin
nacetyldglucosamin
n
methacrylamidenisopropylacrylamid
hpmanipam
also
investig
intranas
vaccin
respiratori
virus
overal
polymer
nanoparticl
mani
advantag
includ
biocompat
antigen
encapsul
stabil
control
releas
antigen
intracellular
persist
apc
pathogenlik
characterist
suitabl
intranas
administr
nevertheless
effect
polym
properti
core
chemistri
size
shape
surfac
properti
transport
within
urt
remain
unknown
studi
need
better
understand
effect
chang
nanoparticl
properti
biolog
activ
ultim
predict
fate
nanocarri
upon
intranas
administr
selfassembl
protein
nanoparticl
sapn
structur
obtain
oligomer
monomer
protein
protein
build
block
mostli
obtain
recombin
technolog
consid
safe
biomed
applic
sapn
engin
diamet
rang
nm
similar
size
mani
virus
therefor
consid
nanovaccin
candid
virus
includ
respiratori
virus
exampl
sanp
design
elicit
immun
respons
rsv
explor
use
nucleoprotein
n
viru
nucleocapsid
n
protein
major
target
antigenspecif
cytotox
tcell
respons
selfassembl
n
protein
protom
led
format
supramolecular
nanor
nm
diamet
platform
modifi
fuse
fsii
epitop
target
monoclon
neutral
antibodi
palivizumab
nprotein
order
form
chimer
nanor
enhanc
immun
respons
viru
protect
rsv
result
show
reduc
viru
load
lung
challeng
mice
similarli
chimer
nanor
display
repeat
highli
conserv
ectodomain
influenza
viru
matrix
protein
prepar
recombin
technolog
administr
via
intranas
rout
nanor
induc
local
product
mucos
antibodi
led
mice
protect
nnanor
interest
intranas
deliveri
antigen
due
similar
respiratori
virus
term
size
structur
subnucleocapsidlik
superstructur
exampl
sapn
potenti
nanovaccin
respiratori
virus
includ
capsid
protein
papaya
mosaic
viru
papmv
purifi
coronaviru
spike
protein
ferritin
selfassembl
protein
form
rodshap
nearli
spheric
nanostructur
respect
recent
assembl
compos
four
tandem
copi
headless
ha
protein
prepar
stabil
sulfosuccinimidyl
propion
crosslink
show
possibl
gener
protein
nanoparticl
almost
entir
compos
antigen
interest
vlp
spheric
supramolecular
assembl
nm
diamet
result
selfassembl
viral
capsid
protein
particl
free
genet
materi
advantag
mimick
perfectli
structur
antigen
epitop
correspond
nativ
virus
therefor
repetit
antigen
display
promot
effici
phagocytosi
apc
subsequ
activ
recent
lee
colleagu
demonstr
intranas
deliveri
influenzaderiv
vlp
express
insect
cell
expos
repeat
epitop
confer
cross
protect
differ
serotyp
influenza
virus
induc
humor
cellular
immun
respons
sapn
vlp
thu
attract
formul
stabl
spray
dri
vaccin
intranas
inject
challeng
may
requir
use
surfact
saccharid
last
decad
selfassembl
peptid
sap
also
investig
intranas
nanovaccin
respiratori
virus
due
straightforward
chemic
synthesi
storag
stabil
upon
lyophil
mani
inorgan
nanoparticl
suitabl
biomed
applic
includ
superparamagnet
nanoparticl
iron
oxid
nanoparticl
quantum
dot
plasmon
nanoparticl
gold
silver
nanoparticl
inorgan
materi
mostli
use
tool
improv
therapeut
efficaci
biodistribut
pharmacokinet
howev
inher
plain
inorgan
core
nanoparticl
would
suitabl
biolog
fluid
due
particl
aggreg
therefor
medic
field
nanoparticl
often
coat
organ
molecul
via
adsorpt
chemic
reaction
fact
biocompat
nanoparticl
describ
complex
hybrid
materi
inorgan
core
organ
outer
shell
among
inorgan
nanoparticl
commonli
use
vaccin
gold
nanoparticl
aunp
aunp
readili
intern
macrophag
dendrit
cell
induc
activ
larg
scale
product
possibl
strict
control
particl
size
eas
function
use
strong
affin
thiol
group
gold
thiol
group
attach
aunp
surfac
form
thiolateau
bond
furthermor
immun
respons
elicit
toward
inert
carrier
like
aunp
thu
nanoparticl
appeal
platform
nanovaccin
engin
via
antigen
function
wide
rang
molecul
includ
adjuv
antigen
conjug
aunp
high
densiti
result
improv
immunogen
antigen
present
aunp
formul
intranas
administr
diffus
lymph
node
trigger
robust
antigenspecif
cytotox
tcell
immun
respons
tao
cowork
demonstr
peptid
consensu
influenza
virus
nonn
cystein
residu
ctermin
end
could
attach
aunp
via
thiolateau
chemistri
result
administ
intranas
rout
mice
cpg
cytosineguanin
rich
oligonucleotid
adjuv
trigger
fulli
protect
immun
respons
influenza
viru
strain
recent
demonstr
formul
could
induc
lung
b
cell
activ
robust
serum
igg
respons
stimul
subclass
addit
vaccin
strategi
led
protect
infect
pandem
influenza
viru
strain
pandem
strain
influenza
viru
strain
highli
pathogen
avian
influenza
viru
although
gold
nanoparticl
constitut
attract
platform
antigen
conjug
accumul
organ
liver
spleen
long
period
could
ultim
associ
toxic
coat
biocompat
materi
reduc
toxic
although
lead
alter
physicochem
biolog
properti
therefor
safeti
issu
aunp
still
need
address
engin
nanoparticl
demonstr
potenti
vaccin
deliveri
platform
envisag
antigen
nanocarri
adjuv
case
intranas
administr
nanovaccin
allow
conveni
safe
deliveri
antigen
nalt
induc
mucos
system
immun
nonetheless
addit
studi
still
need
clinic
translat
intranas
vaccin
nanoparticl
gener
specif
iga
antibodi
urt
lead
high
surviv
rate
anim
model
still
limit
studi
nonhuman
primat
thu
make
nanoparticl
fate
difficult
predict
human
urt
addit
nanoparticl
vaccin
gener
function
specif
antigen
result
immun
respons
target
antigen
determin
consid
antigen
drift
grow
human
popul
need
vaccin
differ
type
virus
cost
address
aspect
would
prohibit
produc
afford
vaccin
consequ
develop
broad
spectrum
vaccin
constitut
critic
need
consid
nanovaccin
engin
contribut
achiev
object
sah
lg
doa
sb
dea
particip
write
prepar
manuscript
approv
public
